Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YS 110

Next Previous
X
Search
Drug Profile

YS 110

Alternative Names: Humanized anti-CD26 monoclonal antibody - Kissei; YS110; YSCMA

Latest Information Update: 28 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ys Therapeutics
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Dipeptidyl peptidase 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Mesothelioma
  • No development reported Renal cell carcinoma

Most Recent Events

  • 28 Sep 2022 No recent reports of development identified for phase-I development in Mesothelioma in France (IV, Infusion)
  • 28 Sep 2022 No recent reports of development identified for phase-I development in Renal-cell-carcinoma in France (IV, Infusion)
  • 18 Sep 2020 Phase I/II development is ongoing for Mesothelioma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan and phase I development for Renal cell carcinoma and Mesothelioma is underway in France (Ys Therapeutics pipeline, September 2020)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top